LCDX (Caliber Imaging & Diagnostics) YoY EBITDA Growth: -75.00% (As of Mar. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Caliber Imaging & Diagnostics YoY EBITDA Growth?

Caliber Imaging & Diagnostics LCDX YoY EBITDA Growth is -75.00% as of Mar. 2014.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Caliber Imaging & Diagnostics's YoY EBITDA Growth for the quarter that ended in Mar. 2014 was -75.00%.

Caliber Imaging & Diagnostics's EBITDA per Share for the three months ended in Mar. 2014 was $-0.19.

Caliber Imaging & Diagnostics YoY EBITDA Growth Related Terms

Caliber Imaging & Diagnostics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Caliber Imaging & Diagnostics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliber Imaging & Diagnostics YoY EBITDA Growth Chart

Caliber Imaging & Diagnostics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13
YoY EBITDA Growth
0.00 -7.53 -72.97 60.62 52.59

Caliber Imaging & Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.53 55.67 46.24 -11.65 -75.00

Caliber Imaging & Diagnostics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Caliber Imaging & Diagnostics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2013 is calculated as:

YoY EBITDA Growth (A: Dec. 2013 )
=(EBITDA per Share (A: Dec. 2013 )-EBITDA per Share (A: Dec. 2012 ))/ | EBITDA per Share (A: Dec. 2012 ) |
=(-0.558--1.177)/ | -1.177 |
=52.59 %

Caliber Imaging & Diagnostics's YoY EBITDA Growth for the quarter that ended in Mar. 2014 is calculated as:

YoY EBITDA Growth (Q: Mar. 2014 )
=(EBITDA per Share (Q: Mar. 2014 )-EBITDA per Share (Q: Mar. 2013 )) / | EBITDA per Share (Q: Mar. 2013 )) |
=(-0.189--0.108)/ | -0.108 |
=-75.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -75.00% mean?
Caliber Imaging & Diagnostics (LCDX) has a YoY EBITDA Growth of -75.00% as of Mar. 2014. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' YoY EBITDA Growth too high?
Caliber Imaging & Diagnostics' current YoY EBITDA Growth is -75.00%.
How does Caliber Imaging & Diagnostics' YoY EBITDA Growth compare to VICA and CRVW?
Caliber Imaging & Diagnostics' YoY EBITDA Growth of -75.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Caliber Imaging & Diagnostics and its competitors. Caliber Imaging & Diagnostics's current YoY EBITDA Growth is -75.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current YoY EBITDA Growth of -75.00%. The current YoY EBITDA Growth is -75.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current YoY EBITDA Growth is -75.00% as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caliber Imaging & Diagnostics Business Description

Address 50 Methodist Hill Drive, Suite 1000, Rochester, NY, USA, 14623
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.